Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansion
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate

